Scarica l'app Stockscreener
54.14
2.69%
1.42
Dopo l'orario di chiusura:
54.14
Tarsus Pharmaceuticals Inc Borsa (TARS) Ultime notizie
Grading 2 Pharma Stocks That Are Heating Up as Large-Cap Rivals Falter - TheStreet Pro
Stocks To Watch: Tarsus Pharmaceuticals Sees RS Rating Jump To 87 - Investor's Business Daily
Tarsus Pharmaceuticals Q2 2025: Key Contradictions on XDEMVY's Market Potential, Discount Strategies, and Seasonal Sales Trends - AInvest
Tarsus Pharmaceuticals’ Earnings Call Highlights XDEMVY Success - TipRanks
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $75 - 富途牛牛
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q2 2025 Earnings Call Transcript - Insider Monkey
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates - MSN
Tarsus Pharmaceuticals shares fall 7.01% after-hours following Q2 2025 earnings call. - AInvest
Tarsus Pharmaceuticals Reports Record Q2 Net Sales of $102.66M, Exceeding Consensus - AInvest
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $84 - 富途牛牛
Tarsus Pharmaceuticals: Strong Sales Growth and Strategic Initiatives Drive Buy Rating - TipRanks
Tarsus targets 95,000–100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum - MSN
Tarsus Pharmaceuticals: Scaling a High-Growth Eye Care Platform with a Diversified Pipeline and Strong Commercial Execution - AInvest
Tarsus Pharmaceuticals Sees 95,000-100,000 Bottles Target for Q3 2025 Amid Record-Breaking Sales - AInvest
Tarsus Pharmaceuticals Reports Record Sales Growth - TipRanks
Transcript : Tarsus Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Tarsus 2025 Q2 Earnings Loss Narrows as Revenue Surges 151.5% - AInvest
Tarsus Pharmaceuticals : Second Quarter 2025 Earnings Presentation - MarketScreener
Tarsus Pharmaceuticals Q2 revenue beats expectations - MarketScreener
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - The Globe and Mail
Tarsus Pharmaceuticals Reports Record $102.7 Million in Quarterly Net Product Sales of XDEMVY, a 152% Increase Year Over Year - Quiver Quantitative
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements - Yahoo Finance
Published on: 2025-08-04 16:33:09 - beatles.ru
How does Tarsus Pharmaceuticals Inc. compare to its industry peersProven strategies for superior portfolio growth - Jammu Links News
What are the technical indicators suggesting about Tarsus Pharmaceuticals Inc.Maximize gains with timely market signals - Jammu Links News
Is Tarsus Pharmaceuticals Inc. stock overvalued or undervaluedRapid growth opportunities - Jammu Links News
Why is Tarsus Pharmaceuticals Inc. stock attracting strong analyst attentionBuild wealth steadily with smart stock selection - Jammu Links News
Is Tarsus Pharmaceuticals Inc. a good long term investmentUnlock powerful stock screening for profits - Jammu Links News
Is it the right time to buy Tarsus Pharmaceuticals Inc. stockGet ahead with breakthrough trading ideas - Jammu Links News
When is Tarsus Pharmaceuticals Inc. stock expected to show significant growthAchieve rapid financial growth with smart picks - Jammu Links News
What is the dividend policy of Tarsus Pharmaceuticals Inc. stockUnlock your portfolio’s full growth potential - Jammu Links News
What are the latest earnings results for Tarsus Pharmaceuticals Inc.Phenomenal returns - Jammu Links News
What analysts say about Tarsus Pharmaceuticals Inc. stockBuild a portfolio that withstands market volatility - Jammu Links News
What institutional investors are buying Tarsus Pharmaceuticals Inc. stockInvest confidently with market-leading analysis - Jammu Links News
How strong is Tarsus Pharmaceuticals Inc. company’s balance sheetAchieve breakthrough financial results - Jammu Links News
What makes Tarsus Pharmaceuticals Inc. stock price move sharplyFree Stock Review Backed By Experts - jammulinksnews.com
Is Tarsus Pharmaceuticals Inc. a growth stock or a value stockChart Pattern Data Feed For Beginners - jammulinksnews.com
Tarsus Pharmaceuticals, Inc. to Host Live Webcast for Q2 2025 Financial Results and Corporate Update - Quiver Quantitative
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - GlobeNewswire Inc.
Why Investors Shouldn't Be Surprised By Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) P/S - simplywall.st
Tarsus Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayWeekly Return Pick Forecast Reports Show Trend - metal.it
Tarsus Pharmaceuticals Inc. Charts Flash Early Recovery SignalsNews Based Entry Opportunity Alerts Detected - metal.it
Tarsus Pharmaceuticals Inc. Facing Inflection Point in Trend AnalysisLong Hold Safe Return Strategy Reviewed - metal.it
Wyckoff Accumulation Phase Possible in Tarsus Pharmaceuticals Inc.Chart-Based Trade Entries Gain Analyst Support - metal.it
Evaluating Tarsus Pharmaceuticals Inc. with trendline analysisTechnical Screener for High Growth Stocks - Newser
How Resilient Is Tarsus Pharmaceuticals Inc. Stock During Economic DownturnsBuy Strategy Tracker with Growth Indicators - Newser
Tarsus Pharmaceuticals Inc. Attempts Reversal From Key SupportChart Driven High Reward Trading Setup Presented - metal.it
Why Tarsus Pharmaceuticals Inc. stock attracts strong analyst attentionTrade Safety Matrix for Conservative Traders - Newser
Published on: 2025-07-28 23:18:28 - metal.it
Fibonacci Levels Suggest Recovery for Tarsus Pharmaceuticals Inc.Weekly Chart Analysis With Entry Advice Provided - metal.it
How volatile is Tarsus Pharmaceuticals Inc. stock compared to the marketTriple-digit profit margins - jammulinksnews.com
Published on: 2025-07-27 21:08:22 - Jammu Links News
Tarsus Pharmaceuticals Inc. Stock Performance After Earnings: Historical InsightsFree Access to Community - metal.it
0.11%
1.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):